Compliance
Office-use compounding rules by state
Whether a prescriber may keep compounded medications on the shelf is decided by state law, and among the states reviewed here the answers are not close. A small group permits it outright as a matter of that state's own pharmacy law: Texas, South Carolina, Alabama, Kansas and Nebraska each grant it without attaching any federal condition. Kansas is the one to read first, because its permission reaches sterile preparations in the rule's own words rather than by inference, and sterile is the limb an injectable lives in; Nebraska writes office use as one of the purposes for which compounding may happen at all, rather than as an exception to a prohibition. North Carolina grants it while conditioning that grant on federal law, and Utah belongs with North Carolina rather than with Kansas and Nebraska: its statute is express and carries no federal hook, but the division's implementing rule is a single sentence re-granting the authority on condition of compliance with the federal Food, Drug, and Cosmetic Act. Connecticut belongs in the first group for non-sterile preparations only, capped at a thirty-day supply — for sterile product it confines a pharmacy to patient-specific supply, which is why its answer has to be given by limb. New Jersey, Missouri and Minnesota bar human office use outright. Georgia and Iowa close the pharmacy route but not the question: Georgia's rule says in terms that it does not affect the ability of outsourcing facilities to supply non-patient-specific preparations for office use, and Iowa defines office use as product from an outsourcing facility in the first place, so both belong with the states that reroute rather than with the states that ban. Mississippi bars the non-patient-specific version while expressly permitting a pharmacy to compound patient-specific medications for office administration by a practitioner, so both halves have to be stated together; Illinois permits it for non-sterile preparations only, the same shape as Connecticut; Ohio's carve-out is narrow and internally contested; Louisiana, Missouri and Iowa authorise only a veterinary pathway, and New Mexico has written no human provision at all while granting two express veterinary ones. Arkansas cannot be answered with a single verdict in either direction: its legislature expressly authorised an outsourcing facility to sell compounded product to a licensed provider for administration in a medical clinic in 2025, and left the pharmacy side unwritten. New England and Delaware sharpen that same point into the most useful distinction on this page, because several of them answer the question with a facility type rather than with a no. Delaware puts it in a single sentence whose operative first word is Only: only an FDA-registered outsourcing facility that also holds a Delaware licence may supply a practitioner for office use. Rhode Island requires a prescription for the compounding of all pharmaceuticals and then excepts outsourcing facilities by name, and Vermont's rule says in terms that 503B outsourcers need not register as compounding pharmacies. Massachusetts is the most distinctive of all and the one most often described wrongly: it does not prohibit office use, it reclassifies the supplier, providing that compounding and distributing sterile preparations in volumes inconsistent with normal patient-specific prescribing, or without accountability documentation, is itself operating as an outsourcing facility — which then carries federal manufacturing-quality standards and FDA registration. Maine closes the pharmacy route by an exhaustive definition whose only non-patient-specific limb is veterinary, and Vermont's veterinary limb goes further than most by contemplating resale by the clinic. New Hampshire is the exception in that group: it expressly permits compounding for office use, but only for products that are not commercially available, and the board rule beneath that statute has not been readopted since 2015 and appears to have lapsed. So for a practice that can reach an outsourcing facility, a state described elsewhere as restrictive is often an open door, and the question worth asking is which kind of facility may supply you rather than whether anyone may. The rest are narrower than they look: Maryland reaches ophthalmologists alone, for six named conditions in emergency treatment; Virginia allows it only where there is a critical need to treat an emergency condition; Tennessee only where the product is not commercially available; Michigan only where the state has authorized that particular pharmacy for that particular prescriber; Washington only by leaving the activity out of the definition of manufacture; Oregon permits it only for radiopharmaceuticals and reclassifies the rest as manufacturing; Indiana forbids it unless federal law is satisfied, in a chapter written for bulk drug substances; Pennsylvania wrote no rule at all and hands the question to federal law. And a growing group used to permit more than it does now: Nevada repealed its permission for compounded drugs in two steps in 2024, Kentucky's rule expired in 2020 and only a veterinary replacement followed, Oklahoma revoked both of its rules and has written nothing in nine years, and Wisconsin repealed its own without yet replacing it. That is why the last-change column matters as much as the verdict, and why a citation to any rule in this family should be re-checked before it is relied on. The mountain and northern-plains entries added most recently sharpen both ends of the range. North Dakota gives the clearest answer on this page: its rule is captioned for office use and permits it, and the permission is conditioned on the supplier rather than on the drug or the quantity — the preparation must come from a facility licensed as an outsourcing facility or from a resident North Dakota pharmacy, and sales to other clinics are called manufacturing that is not allowed. Wyoming states the routing pattern more plainly than anywhere else here, providing that a prescription order for office use is not a valid order while separately requiring an outsourcing facility to carry a label saying the drug is compounded and for office use only. Idaho cannot be given a single answer: its statute excepts the sale of minimal quantities to practitioners for office use from a list of unlawful acts, its definition of compounding is patient-tailored, and the board rule chapter that sat between those texts was voided in its entirety on 1 July 2025 — so the split is the finding. South Dakota wrote neither an authority nor a prohibition, and the closed reading given here is a structural inference from its patient-tethered definitions rather than a quoted holding. Montana has legislated neither way, the term appearing nowhere in its own statutes or rules, and a rulemaking that would close that silence was pending when this page was written. West Virginia is the one entry carrying no verdict at all, because its statute is silent and the rules that would decide it have not been read — which the page says in its own voice rather than filling the gap. The last three close the map, and the most useful of them is a warning about method. Alaska permits a pharmacist to supply a prescribing practitioner for administration to a patient, and that sentence is in neither its statutes nor its administrative code: it lives in a Board of Pharmacy pamphlet dated February 2008 that the code adopts by reference and the state does not publish online, so reading the code alone produces a confident and wrong report of silence. The District of Columbia performs the Massachusetts move and lands somewhere new, because it has no outsourcing-facility category under any name: supplying a practitioner makes the pharmacy a wholesaler and sends it to a generic manufacturer, distributor and wholesaler registration instead. Hawaii has legislated in neither direction, and its one express channel for stock that is not tied to a named patient — the emergency-kit rule — turns on a conflict between a rule that excludes private practice from the term institutional facility and a statute that includes a prescribing practitioner's office in it, which only the Hawaii board can settle. Every US state and the District of Columbia is now listed in the table below with its own rule text, so nothing here is unreviewed; what varies is how much each jurisdiction has actually settled, and the pages that decline to answer say so.
“Office use” means a pharmacy supplying a prescriber with compounded preparations that are not tied to a named patient, for the prescriber to administer in practice. It is one of the most commonly misstated areas of compounding regulation, usually in the direction of describing a state as permissive when its rule text says the opposite.
Every quote below was taken from the state’s own code or board publication. Where a source could not be verified, or where two official sources disagree, that is stated on the page rather than smoothed over.
The federal backdrop governs everything below
Federal law sets the floor. 21 U.S.C. § 353a suspends three federal requirements for compounded drugs, but only on a condition:
Sections 351(a)(2)(B), 352(f)(1), and 355 of this title shall not apply to a drug product if the drug product is compounded for an identified individual patient based on the receipt of a valid prescription order
Section 353a(a)(2) allows compounding “in limited quantities before the receipt of a valid prescription order” on an established prescribing history — but that stock is still dispensed against a patient-specific prescription.
This matters commercially because several of the states below condition office use on “applicable federal law” or expressly incorporate § 353a. In those states the state rule does not independently authorise anything; it hands the question back to federal law. A state rule saying “office use is permitted, consistent with federal law” is not a green light, and should never be read as one. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — see 503A vs 503B.
Every state reviewed, compared
Read the status column as the state’s own words where possible. The differences in the remaining columns — quantity caps, mandatory label legends, reporting duties — are where operational compliance actually lives.